Abstract: A bipolar transistor includes a collector layer, a base layer, and an emitter layer that are formed in this order on a compound semiconductor substrate. The emitter layer is disposed inside an edge of the base layer in plan view. A base electrode is disposed on partial regions of the emitter layer and the base layer so as to extend from an inside of the emitter layer to an outside of the base layer in plan view. An insulating film is disposed between the base electrode and a portion of the base layer, with the portion not overlapping the emitter layer. An alloy layer extends from the base electrode through the emitter layer in a thickness direction and reaches the base layer. The alloy layer contains at least one element constituting the base electrode and elements constituting the emitter layer and the base layer.

Abstract: A filter device includes a piezoelectric substrate, a dielectric layer on the piezoelectric substrate, a first IDT electrode on the dielectric layer, a second IDT electrode positioned on the piezoelectric substrate in an area where the dielectric layer is not provided such that the first and second IDT electrodes are side by side in an acoustic wave propagation direction extending along a principal surface of the piezoelectric substrate, a first reflector on the dielectric layer and adjacent to the first IDT electrode on a side of the second IDT electrode, and a second reflector on the piezoelectric substrate and adjacent to the second IDT electrode on a side of the first IDT electrode. The dielectric layer includes an edge portion between the first and second reflectors in planar view seen from a stacking direction of the piezoelectric substrate and the dielectric layer.

Abstract: Disclosed is a switching valve having a small contact resistance when a valve body moves along a seating surface of a housing. In a switching valve which includes a valve body, coming into contact with a seating surface of a housing having a plurality of ports and selectively communicating at least two ports of the plurality of ports, and applies a fluid pressure to a back surface of the valve body, the switching valve includes a biasing member configured for biasing the valve body in a direction in which the valve body is moved away from the seating surface of the housing.

Abstract: Provided is a method for altering a targeted site of a DNA in a cell, including a step of stimulating the cell with a factor inducing a DNA modifying enzyme endogenous to the cell, and bringing a complex of a nucleic acid sequence-recognizing module specifically binding to a target nucleotide sequence in a given DNA and a DNA modifying enzyme-binding module bonded to each other into contact with the DNA to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site.

Abstract: A stacked semiconductor device capable of increasing heat dissipation comprises a first member and a second member. The first member includes a semiconductor substrate and a first electronic circuit. The first electronic circuit includes a semiconductor element provided on one surface of the semiconductor substrate. A second member is attached to a first surface, which is one surface of the first member. The second member includes a second electronic circuit including another semiconductor element. The second member is provided with a first opening that penetrates the second member in a thickness direction. A first conductor projection is coupled to the first electronic circuit. The first conductor projection protrudes from the first surface of the first member through the first opening of the second member to the outside of the first opening.

Abstract: A semiconductor module comprises a first member including a semiconductor substrate made of a compound semiconductor and a first electronic circuit on the semiconductor substrate is mounted on a mounting surface of a module substrate, and a second member including a semiconductor layer formed of a single semiconductor thinner than the semiconductor substrate of the first member and a second electronic circuit on the semiconductor layer is bonded to an upper surface of the first member. First and second pads are respectively connected to the first electronic circuit on the first member and the second electronic circuit on the second member. A first wire connects the first pad and a substrate side pad. A second wire connects the second pad and a substrate side pad. An inter-member connection wire made of a conductor film on the first and second members connects the first and second electronic circuits.

Abstract: The present invention provides novel antisense oligonucleotide pharmaceutical compositions having higher RNA aggregate-removing activity than conventional pharmaceutical compositions. The pharmaceutical composition of the present invention contains an oligonucleotide having any base sequence of a repeated sequence in which cytosine-adenine-guanine trinucleotides are repeated 5 to 13 times, from the 5? end to the 3? end, and the oligonucleotide has a mixmer structure containing at least two types of RNase H inactive nucleotide analogs. The present invention provides the pharmaceutical composition of the present invention used for the treatment of some symptoms of myotonic dystrophy type 1 disease.

Abstract: A cultured spherical body that is capable of easily performing quantitative analysis of a region containing brain neurons, useful as a supply source of neurons for transplantation, and can be used suitably for drug discovery screening for neurological diseases and compound evaluation systems is obtained. Provided are a cultured spherical body including a first cell layer containing neural stem cells and/or neural progenitor cells and a second cell layer containing brain neurons, wherein the first cell layer is present in the superficial portion of the cultured spherical body, and a method for producing the cultured spherical body.

Abstract: A resin composition for a medical device to be subjected to gas low-temperature sterilization includes a resin and an ion exchanger.

Abstract: Provided is a valve with high pressure resistance. In a valve which is axially driven by a drive source to move a valve body to contact and separate from a valve seat in a valve chamber to control a fluid, a diaphragm has a center axially sandwiched by the valve body and a rod of the drive source and partitions the valve chamber and the drive source in a sealed state.

Abstract: An ultrasound endoscope includes: an ultrasound transducer including a piezoelectric element that includes a plurality of grooves with a groove filling material filled in the plurality of grooves, the groove filling material including the following (1) to (3): (1) an epoxy resin; (2) at least one filler selected from the group consisting of diamond, aluminum oxide, silicon oxide, silicon carbide, boron carbide, iron oxide (III), chromium oxide (III), and cubic boron nitride; and (3) an aliphatic diol diglycidyl ether.

Abstract: The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.

Abstract: An acoustic lens contains a base material composed of a diorganopolysiloxane or a silicone rubber compound utilizing a diorganopolysiloxane as a main component, and plate-like inorganic compound particles dispersed in the base material.

Abstract: The present invention provides a prophylactic and/or therapeutic agent for Alzheimer's disease containing a compound represented by the formula (I) or the formula (II) or a salt thereof.

Abstract: An expansion valve includes: a main body portion having a valve chamber and a valve seat; a case fixed to the main body portion; and a screw shaft that is driven by driving force of rotation obtained by reducing a rotational movement of a rotor due to the excitation of an excitation portion by a speed reduction mechanism to move a valve body forward and backward. A bellows configured to seal a gap between the inside of the case and the valve chamber is arranged in the valve chamber to be externally fitted onto the valve body, and the rotation of the valve body relative to the main body portion is restricted by a rotation restrictor.

Abstract: An information processing device includes: an acquirer configured to acquire images obtained by imaging cells differentiated from pluripotent stem cells derived from a subject; and a predictor configured to input the images acquired by the acquirer to a model trained on data in which information indicating at least a neurodegenerative disease is associated with the image obtained by imaging the cells of the neurodegenerative disease differentiated from the pluripotent stem cells, and predict an onset of the neurodegenerative disease of the subject or effects of drugs on the neurodegenerative disease, based on output results of the model to which the images were input.

Abstract: There is provided a damper device that can be held in a housing space with simple work. A damper device, which is disposed and used in a housing space formed in a device unit, includes: a damper body that is filled with gas and includes a diaphragm provided with a deformable-action portion formed at a central portion thereof; and an annular clip that holds an outer peripheral edge portion of the damper body and causes a biasing force to act on an inner wall of a cover member, which forms the housing space, in a radial direction.

Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).

Abstract: A piston ring which is resinous includes an annular main body portion having an inner peripheral surface and an outer peripheral surface facing each other and a pair of side surfaces interconnecting the inner peripheral surface and the outer peripheral surface and a joint portion 3 formed in the main body portion. The joint portion has a step shape when viewed from at least one of the pair of side surfaces and the outer peripheral surface. The outer peripheral surface has a tapered surface having an outer diameter increasing from a side of one side surface of the pair of side surfaces of the main body portion toward a side of the other side surface.

Abstract: The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.